Literature DB >> 25147908

A comparison of assay performance between the calcium mobilization and the dynamic mass redistribution technologies for the human urotensin receptor.

Mi Young Lee1, Jihye Mun, Jeong Hyun Lee, Sunghou Lee, Byung Ho Lee, Kwang-Seok Oh.   

Abstract

The popular screening method for urotensin (UT) receptor antagonists is to measure the intracellular calcium concentration with a calcium-sensitive fluorescent dye. This assay format has an inherent limitation on the problem related to the fluorescence interference as it involves fluorescent dyes. In the present study, a label-free assay for the screening of UT receptor antagonists was developed by using dynamic mass redistribution (DMR) assay based on label-free optical biosensor. The addition of urotensin II (UII) stimulated a DMR profile to HEK293 cells stably expressing the human UT receptor (HEK293UT cells) but not on parental cells. The EC50 value of UII in label-free assay was 4.58 nM, which is very similar to that in conventional calcium mobilization assay (4.15 nM). Compared with the calcium mobilization assay for UII (Z' factor, 0.77), the current label-free assay presented improved Z' factor (0.81), with a relatively similar S/B ratio (28.0 and 25.6, respectively). The known high-affinity UT receptor antagonists, SB657510, GSK562590, and urantide, exhibited comparable IC50 values but rather less potent in the DMR assay than in calcium mobilization. Our DMR assay was able to present various functional responses, including inverse agonism in SB657510 and GSK1562590 as well as partial agonism in urantide. Moreover, the DMR assay exerted the stable antagonist window upon the minimal agonist stimulus. These results suggest that the label-free cell-based UT receptor assay can be applicable to evaluate the various functional activities of UT receptor-related drug candidates.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25147908      PMCID: PMC4142844          DOI: 10.1089/adt.2014.590

Source DB:  PubMed          Journal:  Assay Drug Dev Technol        ISSN: 1540-658X            Impact factor:   1.738


  22 in total

1.  A Simple Statistical Parameter for Use in Evaluation and Validation of High Throughput Screening Assays.

Authors: 
Journal:  J Biomol Screen       Date:  1999

Review 2.  Functional assays for screening GPCR targets.

Authors:  William Thomsen; John Frazer; David Unett
Journal:  Curr Opin Biotechnol       Date:  2005-10-28       Impact factor: 9.740

3.  Evaluation of dynamic mass redistribution technology for pharmacological studies of recombinant and endogenously expressed g protein-coupled receptors.

Authors:  Paul H Lee; Alice Gao; Carlo van Staden; Jenny Ly; John Salon; Arron Xu; Ye Fang; Ron Verkleeren
Journal:  Assay Drug Dev Technol       Date:  2008-02       Impact factor: 1.738

4.  Applying label-free dynamic mass redistribution technology to frame signaling of G protein-coupled receptors noninvasively in living cells.

Authors:  Ralf Schröder; Johannes Schmidt; Stefanie Blättermann; Lucas Peters; Nicole Janssen; Manuel Grundmann; Wiebke Seemann; Dorina Kaufel; Nicole Merten; Christel Drewke; Jesus Gomeza; Graeme Milligan; Klaus Mohr; Evi Kostenis
Journal:  Nat Protoc       Date:  2011-10-20       Impact factor: 13.491

5.  Comparing label-free biosensors for pharmacological screening with cell-based functional assays.

Authors:  Matthew F Peters; François Vaillancourt; Madeleine Heroux; Manon Valiquette; Clay W Scott
Journal:  Assay Drug Dev Technol       Date:  2010-04       Impact factor: 1.738

6.  Characteristics of dynamic mass redistribution of epidermal growth factor receptor signaling in living cells measured with label-free optical biosensors.

Authors:  Ye Fang; Ann M Ferrie; Norman H Fontaine; Po Ki Yuen
Journal:  Anal Chem       Date:  2005-09-01       Impact factor: 6.986

7.  GSK1562590, a slowly dissociating urotensin-II receptor antagonist, exhibits prolonged pharmacodynamic activity ex vivo.

Authors:  D J Behm; N V Aiyar; A R Olzinski; J J McAtee; M A Hilfiker; J W Dodson; S E Dowdell; G Z Wang; K B Goodman; C A Sehon; M R Harpel; R N Willette; M J Neeb; C A Leach; S A Douglas
Journal:  Br J Pharmacol       Date:  2010-09       Impact factor: 8.739

8.  Palosuran inhibits binding to primate UT receptors in cell membranes but demonstrates differential activity in intact cells and vascular tissues.

Authors:  D J Behm; J J McAtee; J W Dodson; M J Neeb; H E Fries; C A Evans; R R Hernandez; K D Hoffman; S M Harrison; J M Lai; C Wu; N V Aiyar; E H Ohlstein; S A Douglas
Journal:  Br J Pharmacol       Date:  2008-06-30       Impact factor: 8.739

9.  Functional screening of G protein-coupled receptors by measuring intracellular calcium with a fluorescence microplate reader.

Authors:  Matthias U Kassack; Barbara Höfgen; Jochen Lehmann; Niels Eckstein; J Mark Quillan; Wolfgang Sadée
Journal:  J Biomol Screen       Date:  2002-06

10.  Ligands and signaling of the G-protein-coupled receptor GPR14, expressed in human kidney cells.

Authors:  Ulrike Lehner; Ana Velić; Rita Schroter; Eberhard Schlatter; Aleksandra Sindić
Journal:  Cell Physiol Biochem       Date:  2007
View more
  3 in total

1.  A novel GPER antagonist protects against the formation of estrogen-induced cholesterol gallstones in female mice.

Authors:  Chelsea DeLeon; Helen H Wang; Joseph Gunn; McKenna Wilhelm; Aidan Cole; Stacy Arnett; David Q-H Wang; Christopher K Arnatt
Journal:  J Lipid Res       Date:  2020-03-03       Impact factor: 5.922

2.  A Dynamic Mass Redistribution Assay for the Human Sweet Taste Receptor Uncovers G-Protein Dependent Biased Ligands.

Authors:  Nicole B Servant; Mark E Williams; Paul F Brust; Huixian Tang; Melissa S Wong; Qing Chen; Marketa Lebl-Rinnova; Sara L Adamski-Werner; Catherine Tachdjian; Guy Servant
Journal:  Front Pharmacol       Date:  2022-02-17       Impact factor: 5.810

3.  NOP receptor pharmacological profile - A dynamic mass redistribution study.

Authors:  Davide Malfacini; Katharina Simon; Claudio Trapella; Remo Guerrini; Nurulain T Zaveri; Evi Kostenis; Girolamo Calo'
Journal:  PLoS One       Date:  2018-08-30       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.